Publication:
Retroperitoneal sentinel lymph node biopsy using vNOTES in endometrial cancer patients with a BMI ≥ 30 kg/m2: a pilot multicenter case series by the Turkish gynecologic oncology group (TRSGO-SLN12)

dc.contributor.coauthorGungorduk, Kemal
dc.contributor.coauthorErkilinc, Selcuk
dc.contributor.coauthorKorkmaz, Vakkas
dc.contributor.coauthorHanedan, Candost
dc.contributor.coauthorIscan, Serhan Can
dc.contributor.coauthorGulseren, Varol
dc.contributor.coauthorTaskin, Salih
dc.contributor.coauthorOzerkan, Kemal
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorTaşkıran, Çağatay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-02T07:04:21Z
dc.date.available2026-03-27
dc.date.issued2026
dc.description.abstractAimThis study evaluated the feasibility and surgical outcomes of transvaginal natural orifice transluminal endoscopic surgery (vNOTES) for retroperitoneal sentinel lymph node biopsy (SLNB), specifically targeting obese and morbidly obese patients diagnosed with endometrial cancer (EC).MethodsPathohistological evaluation confirmed the diagnosis of either Grade I or II endometrioid EC in all participants.ResultsIn total, 31 patients participated in this study. The median age was 56 [43-75] years and the median BMI was 34 [30-54] kg/m2. Near-infrared fluorescence imaging utilizing ICG was implemented in 17 cases (54.8%), while methylene blue dye was used in 14 cases (45.2%). A median, 4 sentinel lymph nodes (SLNs) were excised per patient, with numbers ranging from 1 to 7. The overall SLN detection rate was 90.3%, with unilateral detection in 9.7% of patients and bilateral detection in 80.6%. During the surgery, two complications occurred, and an additional two developed afterward. In 3.2% of cases, it was required to switch to a conventional laparoscopic procedure. Lymphatic metastases were identified in 3 patients (9.7%). The median hospital stay was 2 days.ConclusionvNOTES can be a viable alternative to retroperitoneal SLNB, providing distinct benefits, especially for obese and morbidly obese patients with EC.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.1080/13645706.2026.2625069
dc.identifier.eissn1365-2931
dc.identifier.embargoNo
dc.identifier.endpage152
dc.identifier.issn1364-5706
dc.identifier.issue2
dc.identifier.pubmed41664597
dc.identifier.scopus2-s2.0-105029920667
dc.identifier.startpage145
dc.identifier.urihttps://doi.org10.1186/s12987-026-00776-8
dc.identifier.urihttps://hdl.handle.net/20.500.14288/32889
dc.identifier.volume35
dc.identifier.wos001686638200001
dc.keywordsEndometrial cancer
dc.keywordsSentinel lymph node biopsy
dc.keywordsvNOTES
dc.languageeng
dc.publisherTaylor and Francis
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofMinimally Invasive Therapy and Allied Technologies
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectSurgery
dc.titleRetroperitoneal sentinel lymph node biopsy using vNOTES in endometrial cancer patients with a BMI ≥ 30 kg/m2: a pilot multicenter case series by the Turkish gynecologic oncology group (TRSGO-SLN12)
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files